Many　non-surgical　treatments　of　hepatocellular　carcinoma　(HCC)　have　significantly　improved　in　the　last　few　decades　and　have　shown　survival　benefits　for　selected　patients　withHCC.　Today　ablation　can　improve　survival　in　individuals　diagnosed　in　early　HCC　and　even　offer　a　curative　treatment　in　selected　candidates.　Patients　with　intermediate-stage　HCC　benefit　from　transarterial　chemoembolization　(TACE).　Drug-eluting　bead　transarterial　chemoembolization　(DEB-TACE)　has　shown　a　better　combined　ischemic　and　cytotoxic　effect　locally　and　less　system　toxicity　when　compared　with　conventional　TACE.　Those　diagnosed　at　advanced　stage　benefit　from　sorafenib.　In　addition　to　TACE　and　sorafenib　which　could　improve　survival　for　selected　patients,　three-dimensional　conformal　radiotherapy　treatment　(3-DCRT),　selection　internal　radiation　therapy　and　systemic　chemotherapy　have　also　shown　anti-tumor　activity　in　the　treatment　of　advanced　HCC,　but　their　survival　benefit　have　not　been　proven.　The　limited　effects　of　single　therapy　suggested　that　the　combination　would　enhance　the　overall　treatment　effect.　Other　potential　non-surgical　therapies　like　gene　therapy　and　immunotherapy　are　still　in　testing　phases,　except　for　some　small-scale　clinical　trials　which　have　been　reported　to　show　some　beneficial　effect.　Here,　we　review　the　current　non-surgical　treatments　in　HCC　and　the　new　advances　in　this　field.